Viking Therapeutics Released 52-week Histologic Data From Its Phase 2B VOYAGE Study Of VK2809 In Non-Alcoholic Steatohepatitis
Portfolio Pulse from Benzinga Newsdesk
Viking Therapeutics released 52-week histologic data from its Phase 2B VOYAGE study of VK2809 in non-alcoholic steatohepatitis (NASH). The results showed significant improvements in NASH resolution and fibrosis among VK2809-treated patients compared to placebo, with similar adverse events.
June 04, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viking Therapeutics' Phase 2B VOYAGE study of VK2809 in NASH showed significant improvements in NASH resolution and fibrosis compared to placebo, with similar adverse events. This positive data could boost investor confidence and drive the stock price up.
The Phase 2B study results for VK2809 in NASH are highly positive, showing significant improvements in key metrics compared to placebo. This is likely to increase investor confidence and positively impact the stock price of Viking Therapeutics.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100